Zhehuan Zhang, Tianchen Wu, Wenwen Xu, Di Hu, Chenhao Yang
{"title":"类固醇在COVID-19治疗中的眼部隐患:一份病例报告","authors":"Zhehuan Zhang, Tianchen Wu, Wenwen Xu, Di Hu, Chenhao Yang","doi":"10.21037/tp-24-443","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Coronavirus disease 2019 (COVID-19) has been coexisted with us, and corticosteroids are now recommended for patients with severe COVID-19 respiratory failure. Steroid treatments may increase intraocular pressure (IOP) and steroid-induced glaucoma (SIG). This study reported a rapid IOP elevation in a COVID-19 pneumonia child treated with systemic steroids within 3 days. Steroid-induced ocular hypertension (SIOH) during pneumonia treatment has not been previously reported.</p><p><strong>Case description: </strong>The 6-year-old Chinese girl was diagnosed with COVID-19 and presented with pulmonary exudative lesions. Intravenous steroid (methylprednisolone, 1 mg/kg/12 h) was administered to control the inflammatory reaction on the fourth day post-infection. The child complained of ocular pain in the left eye (OS) after 3 days of steroid application. A high IOP of 40 mmHg in the right eye (OD) and 60 mmHg (OS) was detected. Following the exclusion of elevated IOP secondary to COVID-19 infection, SIOH was considered as a potential etiology. The IOP was effectively controlled through prompt tapering of systemic steroids and the immediate initiation of IOP-lowering therapy, including intravenous mannitol and topical antiglaucoma medications.</p><p><strong>Conclusions: </strong>Clinicians treating COVID-19 in hospitals should pay attention to SIOH or SIG risk, especially in pediatric patients.</p>","PeriodicalId":23294,"journal":{"name":"Translational pediatrics","volume":"14 3","pages":"516-521"},"PeriodicalIF":1.5000,"publicationDate":"2025-03-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11982994/pdf/","citationCount":"0","resultStr":"{\"title\":\"The hidden ophthalmic dangers of steroids in COVID-19 treatment: a case report.\",\"authors\":\"Zhehuan Zhang, Tianchen Wu, Wenwen Xu, Di Hu, Chenhao Yang\",\"doi\":\"10.21037/tp-24-443\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Coronavirus disease 2019 (COVID-19) has been coexisted with us, and corticosteroids are now recommended for patients with severe COVID-19 respiratory failure. Steroid treatments may increase intraocular pressure (IOP) and steroid-induced glaucoma (SIG). This study reported a rapid IOP elevation in a COVID-19 pneumonia child treated with systemic steroids within 3 days. Steroid-induced ocular hypertension (SIOH) during pneumonia treatment has not been previously reported.</p><p><strong>Case description: </strong>The 6-year-old Chinese girl was diagnosed with COVID-19 and presented with pulmonary exudative lesions. Intravenous steroid (methylprednisolone, 1 mg/kg/12 h) was administered to control the inflammatory reaction on the fourth day post-infection. The child complained of ocular pain in the left eye (OS) after 3 days of steroid application. A high IOP of 40 mmHg in the right eye (OD) and 60 mmHg (OS) was detected. Following the exclusion of elevated IOP secondary to COVID-19 infection, SIOH was considered as a potential etiology. The IOP was effectively controlled through prompt tapering of systemic steroids and the immediate initiation of IOP-lowering therapy, including intravenous mannitol and topical antiglaucoma medications.</p><p><strong>Conclusions: </strong>Clinicians treating COVID-19 in hospitals should pay attention to SIOH or SIG risk, especially in pediatric patients.</p>\",\"PeriodicalId\":23294,\"journal\":{\"name\":\"Translational pediatrics\",\"volume\":\"14 3\",\"pages\":\"516-521\"},\"PeriodicalIF\":1.5000,\"publicationDate\":\"2025-03-31\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11982994/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Translational pediatrics\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.21037/tp-24-443\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/3/26 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q2\",\"JCRName\":\"PEDIATRICS\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Translational pediatrics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.21037/tp-24-443","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/3/26 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"PEDIATRICS","Score":null,"Total":0}
The hidden ophthalmic dangers of steroids in COVID-19 treatment: a case report.
Background: Coronavirus disease 2019 (COVID-19) has been coexisted with us, and corticosteroids are now recommended for patients with severe COVID-19 respiratory failure. Steroid treatments may increase intraocular pressure (IOP) and steroid-induced glaucoma (SIG). This study reported a rapid IOP elevation in a COVID-19 pneumonia child treated with systemic steroids within 3 days. Steroid-induced ocular hypertension (SIOH) during pneumonia treatment has not been previously reported.
Case description: The 6-year-old Chinese girl was diagnosed with COVID-19 and presented with pulmonary exudative lesions. Intravenous steroid (methylprednisolone, 1 mg/kg/12 h) was administered to control the inflammatory reaction on the fourth day post-infection. The child complained of ocular pain in the left eye (OS) after 3 days of steroid application. A high IOP of 40 mmHg in the right eye (OD) and 60 mmHg (OS) was detected. Following the exclusion of elevated IOP secondary to COVID-19 infection, SIOH was considered as a potential etiology. The IOP was effectively controlled through prompt tapering of systemic steroids and the immediate initiation of IOP-lowering therapy, including intravenous mannitol and topical antiglaucoma medications.
Conclusions: Clinicians treating COVID-19 in hospitals should pay attention to SIOH or SIG risk, especially in pediatric patients.